Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock?
Novo Nordisk's oral semaglutide (Wegovy pill) has reached 3 million prescriptions, a notable adoption milestone for the beaten-down NVO stock. The question is whether this uptake, combined with an 81% gross margin profile, is being overlooked by a market fixated on GLP-1 competitive threats.
What happened
Novo Nordisk's oral semaglutide (Wegovy pill) has reached 3 million prescriptions, a notable adoption milestone for the beaten-down NVO stock.
The read · Jun 20
NVO has been heavily sold off on GLP-1 competition fears, but 3 million oral semaglutide prescriptions raises the question of whether the market has over-discounted the stock relative to its still-exceptional margin structure.
Wrong if
Eli Lilly reports superior efficacy data for oral tirzepatide or accelerates biosimilar entry disrupts the oral semaglutide volume story and re-rates NVO lower.
CoverageSource: Yahoo Finance · Published here SAT, JUN 20 · 12:35 PM ET · the only report in this recordHow this is decided →
The chart · NVOTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
Novo Nordisk's oral semaglutide formulation has crossed 3 million prescriptions, a faster-than-expected ramp that signals real consumer appetite for a pill-based GLP-1 alternative to weekly injections. NVO's underlying financials remain robust — 81% gross margins, 33.1% net margins, and $23.03 diluted EPS on roughly $309B in revenue — yet the stock has been materially beaten down from its 2024 highs amid fears over Eli Lilly's tirzepatide dominance and potential biosimilar competition.
The 3M prescription milestone could mark an inflection point if oral GLP-1 adoption broadens the total addressable market rather than cannibalizing Ozempic/Wegovy injectable volumes. Key things to watch: oral semaglutide label expansion progress, any updated guidance from NVO management on pill vs. injectable mix, and whether the competitive gap with LLY on efficacy data narrows or widens into the next clinical readouts.
The read, in fullWhy it matters
NVO trades well off its 2024 highs despite maintaining 81% gross margins and $23+ diluted EPS, suggesting the selloff has priced in a worst-case competitive scenario. The 3M oral prescription milestone is a concrete signal that pill-based GLP-1 adoption is real, potentially broadening the TAM rather than purely cannibalizing injectables. If upcoming guidance or clinical data confirms oral semaglutide is additive to the franchise, the valuation discount to intrinsic value narrows sharply.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written · closes shown from JUN 22 on
Next · what would move this
2-4 months. Follow to be told when one lands.
Since this story · named here, equal weight · 1D EOD+2.9%
JUN 22 · first close after publicationSEP 4
Price context does not establish that the story caused the move.
▲ The case it holds
With 81% gross margins, $23+ diluted EPS, and 3 million oral prescriptions already written, the market may be undervaluing NVO's franchise durability — particularly if the oral format expands the GLP-1 user base beyond injection-averse patients.
▼ The case it breaks
Lilly's tirzepatide has demonstrated superior weight-loss efficacy in head-to-head data, and NVO's revenue growth has already decelerated to 6.4% YoY, raising the possibility that the competitive threat to injectable Wegovy is more structural than the bull thesis allows.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →